A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma

Akeso7 sites in 1 country610 target enrollmentSeptember 17, 2021

ConditionsGastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

InterventionsAK104 Placebo

Overview

Phase: Phase 3
Intervention: AK104
Conditions: Gastric Adenocarcinoma
Sponsor: Akeso
Enrollment: 610
Locations: 7
Primary Endpoint: Overall Survival (os)
Status: Completed
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.

Registry

clinicaltrials.gov

Start Date

September 17, 2021

End Date

August 1, 2025

Last Updated

5 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Akeso

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must meet all of the following inclusion criteria to be enrolled in the study:
•Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
•Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.
•Histopathologically confirmed gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma.
•Unresectable locally advanced or metastatic gastric adenocarcinoma or GEJ adenocarcinoma.
•Subjects have not received prior systemic therapy for locally advanced or metastatic gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction. For subjects who have received prior neoadjuvant/adjuvant chemotherapy or chemoradiotherapy for curative intent, the time between disease progression and last treatment should be at least 6 months.
•Subjects have at least one measurable tumor lesion per RECIST v1.1; lesions that received radiotherapy are not selected as target lesions, unless the lesion is the only measurable lesion and has unequivocal progression as judged by imaging, it can be considered as a target lesion.

Exclusion Criteria

•Subjects who meet any of the following criteria are not eligible to participate in this study:
•Subjects with known HER2-positive gastric or GEJ adenocarcinoma.
•Histopathology or cytology confirmed other pathological types, such as squamous cell carcinoma, sarcoma, or undifferentiated carcinoma.
•Subjects who received palliative local therapy for non-target lesions within 2 weeks prior to the first dose; systemic nonspecific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, etc.) within 2 weeks prior to the first dose; and Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 2 weeks prior to the first dose.
•Subjects who received any prior treatments targeting the mechanism of tumor immunity.
•Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose. If the perforation or fistula has been treated with resection or repair and the disease has recovered or resolved as judged by the Investigator, enrollment may be allowed.
•Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
•Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors, such as basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, carcinoma in situ of cervix, carcinoma in situ of breast, localized prostate cancer, etc.
•Known active or untreated brain metastases, meningeal metastases, spinal cord compression, or leptomeningeal disease.
•Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1/month).

Arms & Interventions

AK104 + Oxaliplatin + Capecitabine

AK104 in combination with Oxaliplatin and Capecitabine

Intervention: AK104

Placebo + Oxaliplatin + Capecitabine

Placebo in combination with Oxaliplatin and Capecitabine

Intervention: Placebo

Outcomes

Primary Outcomes

Overall Survival (os)

Time Frame: Up to 2 years

OS in the ITT population.

Secondary Outcomes

TTR(Up to 2 years)
DoR(Up to 2 years)
AE(From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first)
Observed concentrations of AK104(From first dose of AK104 through the last dose of AK104, about average of 9 months.)
ORR(Up to 2 years)
DCR(Up to 2 years)
PFS(Up to 2 years)
Number of subjects who develop detectable anti-drug antibodies (ADAs)(From first dose of AK104 through 30 days after last dose of AK104)